Moderna, Inc. (MRNA)
Moderna Rises 6% Despite GSK Moving Rival mRNA Flu Vaccine to Phase III
Today's major mRNA headline is a competitive threat to Moderna (NASDAQ:MRNA | MRNA Price Prediction), and the stock is climbing anyway.
Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough
Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.
BioNTech Tumbles 8% as Colorectal Cancer Vaccine Trial Fails, Moderna Drops 6%, Pfizer Holds Flat
A single trial readout is reshuffling the mRNA vaccine trade this morning. BioNTech SE (NASDAQ:BNTX | BNTX Price Prediction) stock is down 8% to $102.
Moderna Drops 7% Despite a Fresh Wolfe Research Upgrade, BioNTech Slips
Moderna stock is giving back a large chunk of Tuesday's rally. The pullback reopens a question that a summer melt-up has largely papered over: what does a market capitalization near $59 billion actually value on this income statement?
Was Moderna Stock's 440% Surge Hiding In Plain Sight?
This article was written by Doug Nathman, with research by his team at Trefis.
Moderna Rallies 11%, BioNTech Ticks Up: Is the mRNA Trade Down to One Name?
Two names built on the same platform have stopped moving together this morning. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is up 11% to $154.15, a Tuesday morning session standing well apart from anything happening across the broader biotech sector.
Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.
On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced positive topline Phase 3 results from INTerpath-001 for intismeran autogene, an individualized neoantigen therapy paired with Keytruda in resected melanoma.
Should You Buy Moderna Stock Following Its Cancer Breakthrough?
MRNA's cancer therapy scores a phase III win, strengthening its mRNA platform, while pipeline risks and competition remain key concerns.
Moderna Sinks 7% as Traders Book Profits on a 392% Year-to-Date Surge; BioNTech Drops 4%, Merck Slips
Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is down 7% to $135.22 in Monday morning trading, cooling off after one of the most explosive runs in biotech this year.
How a Big Bet on Cancer Vaccines Brought Moderna Back from the Brink
After years of layoffs, cash burn and political attacks on its core technology, Moderna's melanoma vaccine data notched the biotech company a much-needed win.
Moderna Rallies 8%, BioNTech Climbs 4% as the mRNA Trade Whipsaws for a Third Session
The mRNA trade is whipsawing for a third straight session as the market keeps repricing a single trial readout with no fresh clinical information hitting the tape Friday.
Moderna's 177% Surge Has Investors Asking What Comes Next
It's not every day that a company already worth billions sees its shares nearly triple in a single trading session. Welcome to the world of biotech, because that's exactly what happened to Moderna Inc. NASDAQ: MRNA on Wednesday of this week, after the Massachusetts-based company stunned the market with a breakthrough that sent its stock rocketing to a multi-year high.
